Pharmacist Care Could Reduce Cancer Treatment Reactions
Patients with hematologic malignancies saw lower drug reaction rates when pharmacists managed their medications.
Updated on Oct. 22, 2026 in Cancer
Live Poll
Should medical centers integrate dedicated pharmacists into oncology teams to improve medication safety?
A clinical trial involving 182 patients found that integrated oncology pharmacist care significantly reduced adverse drug reactions in those with hematologic malignancies. This pharmacist-led intervention, which cost $105 per patient, successfully identified and mitigated medication errors during cancer treatment.
Why it matters
Complex cancer regimens often carry high risks for toxicities, and this study suggests that dedicated pharmacist oversight can improve patient safety. By catching errors and recommending adjustments, this model offers a cost-effective strategy to manage medication risks in high-stakes oncology settings.
In a clinical trial of 182 patients with hematologic malignancies, pharmacist-led care resulted in an adverse drug reaction rate of 23.1% compared to 47.3% in the standard care group. While these preliminary findings suggest significant safety benefits, larger multicenter studies are still required.
The players
Hematology/Oncology Pharmacy Association
A professional organization that establishes clinical practice guidelines and standards for oncology pharmacists.
The details
The intervention involved oncology pharmacists performing direct medication assessments, patient counseling, and providing treatment recommendations that physicians implemented 95% of the time. Pharmacists issued 588 recommendations during the 5-month study, identifying 287 instances of medication errors. This specialized oversight helped manage complex drug regimens by systematically addressing therapy-related toxicities and dosing inaccuracies.
Timeline
• Data collection occurred from July 2020 through October 2022.
• A systematic review regarding scope of practice is expected in 2026.
Health Landscape
This research aligns with ongoing efforts by the Hematology/Oncology Pharmacy Association to define the scope of practice for oncology-specialized pharmacists. It reinforces the trend toward integrated, multidisciplinary care models that prioritize medication safety for patients undergoing complex cancer therapies.
Patients undergoing intensive treatment for hematologic cancers should discuss the role of oncology pharmacists in their care plan with their primary physician. Clarifying how medication reviews and counseling are integrated into your routine can help identify potential adverse reactions early.
The takeaway
Dedicated pharmacist oversight can significantly reduce medication errors and adverse reactions in cancer patients. Patients should ask their healthcare team about the availability of a clinical pharmacist to review their medication regimen during active treatment.
Further reading
For more on evolving standards, see our Cancer section.
More information
Review the Hematology/Oncology Pharmacy Association scope of practice for details on clinical guidelines.
Source note: This article includes information reported by Pharmacytimes.
Live Poll
Should medical centers integrate dedicated pharmacists into oncology teams to improve medication safety?
